Increased cell survival upon ARMC5 inactivation is proposed to trigger hyperplasia while subclinical CS could be the result of the major increase in adrenal mass that would compensate for decreased per-cell steroidogenic activity. The gene discussed is ARMC5; the disease is Cowden syndrome 1.